Piersma Sytse J, Welters Marij J P, van der Burg Sjoerd H
Department of Clinical Oncology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Hum Immunol. 2008 Apr-May;69(4-5):241-9. doi: 10.1016/j.humimm.2008.02.005. Epub 2008 Mar 28.
A large body of evidence indicates that the presence of regulatory T cells (Tregs) in tumors is associated with a dampened tumor-specific immune response and a clear negative impact on survival. Many different subsets of Tregs have been identified, which all act through similar or distinct pathways to suppress tumor-specific effector cells. The observation that tumor-infiltrating Tregs are able to recognize tumor-derived antigens and can be expanded by vaccines that primarily aim at reinforcing the effector arm of the antitumor response stresses the need to study Tregs for each type of cancer targeted by immunotherapy. Current protocols enable us to isolate and culture tumor-infiltrating Tregs. Ultimately, this will not only lead to a full comprehension of the specificity and working mechanisms of Tregs but also facilitate the development of successful interventions strategies for the immunotherapy of cancer.
大量证据表明，肿瘤中调节性T细胞（Tregs）的存在与肿瘤特异性免疫反应减弱以及对生存率产生明显负面影响有关。已鉴定出许多不同的Tregs亚群，它们都通过相似或不同的途径来抑制肿瘤特异性效应细胞。肿瘤浸润性Tregs能够识别肿瘤衍生抗原，并且可以通过主要旨在增强抗肿瘤反应效应臂的疫苗进行扩增，这一观察结果强调了针对免疫疗法所靶向的每种癌症研究Tregs的必要性。当前的方案使我们能够分离和培养肿瘤浸润性Tregs。最终，这不仅将全面理解Tregs的特异性和作用机制，还将促进癌症免疫疗法成功干预策略的开发。
